SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial

HUMMELSTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced the first patient has been dosed in the Company’s Phase 1, first-in-human, multi-center study evaluating SIRPant-M™ alone or in combination with focal external-beam radiotherapy (XRT) in patients with relapsed/refractory Non-Hodgkin lymphoma (R/R-NHL).

“The culmination of years of development work, initially in Academia, and later taken forward by SIRPant, we are pleased to announce the dosing of the first patient in this Phase 1 study evaluating SIRPant-M™, last week at the City of Hope Cancer Center.”, said Jelle Kijlstra, M.D., Chief Medical Officer of SIRPant. “With its unique polyclonal mechanism of action, relying on tumor-specific neo-antigens, SIRPant-M™ is well positioned to reveal the therapeutic potential of activated macrophage cell-therapy, and we look forward to providing updates as early outcomes emerge in in 2024.” Read More